Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Imaging Diagnostic Systems, Inc., a pioneer in laser optical breast imaging, has redefined its marketing strategy and launched a new campaign focusing on the international market. While attending the Arab Health Exhibition and Congress in Dubai, United Arab Emirates from January 26-29, 2009, IDSI company management secured new distributors for the United Arab Emirates and hired a Managing Director to market the CT Laser Mammography System ( CTLM (R)) in the UAE and parts of the Middle East.

"This is one of the many international conferences we will be attending in hopes to retain new distributors to market our CTLM system. We are disappointed with the performance of our previous distributors, which inspired this new direction for our international marketing efforts," stated Deborah O'Brien, Senior Vice President of Imaging Diagnostic Systems. "Arab Health was very beneficial to us as it enabled us to meet with dignitaries and distributors from around the Middle East who are interested in the CTLM system, but are difficult to speak with directly. The system's innovative approach to detecting breast cancer and the discreet method in which the patient is examined was well received. I am confident that this is only the beginning of several distributors we will sign on and gain more sales as a result."

The Company is in negotiations with distributors representing Oman, Egypt, Saudi Arabia, India, Yemen, Belgrade and Syria.

The Arab Health Exhibition and Congress is the premier event for the Middle East, bringing healthcare manufacturers, wholesalers, and distributors together with some of the most important and influential decision-makers in the Arab world. As the second largest exhibition of its kind in the world, with over 3,000 exhibitors from over 65 countries and more than 60,000 medical professionals, it is recognized as an imperative global event for companies to showcase their products in one of the fastest growing and most lucrative healthcare markets in the world.

Imaging Diagnostic Systems, Inc. is seeking FDA Premarket Approval (PMA) for its Computed Tomography Mammography ( CTLM (R)) system to be used as an adjunct to mammography. The Company's PMA application will be submitted in its entirety at the completion of the data collection and review process. The FDA has determined that the Company's clinical investigation is a non-significant risk (NSR) investigational device study because it does not meet the definition of a significant risk (SR) device under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM (R) system is the first patented breast imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000, ISO 13485:2003 certification and FDA export certification for its CT Laser Mammography system. Please visit Imaging Diagnostic Systems' website at: www.imds.com for additional information.

Source: Imaging Diagnostic Systems, Inc.